Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).

Heneghan, Matthew; Southern, Kevin W; Murphy, Jared; Sinha, Ian P; Nevitt, Sarah J

Heneghan, Matthew; Southern, Kevin W; Murphy, Jared; Sinha, Ian P; Nevitt, Sarah J.

Afiliación

Heneghan M; Department of Women's and Children's Health, University of Liverpool, Liverpool, UK.
Southern KW; Department of Women's and Children's Health, University of Liverpool, Liverpool, UK.
Murphy J; Leighton Hospital, Crewe, UK.
Sinha IP; Department of Women's and Children's Health, University of Liverpool, Liverpool, UK.
Nevitt SJ; Department of Health Data Science, University of Liverpool, Liverpool, UK.

Cochrane Database Syst Rev ; 11: CD010966, 2023 11 20.

Article en En | MEDLINE | ID: mdl-37983082

Asunto(s)

Fibrosis Quística; Adulto; Niño; Humanos; Fibrosis Quística/tratamiento farmacológico; Fibrosis Quística/genética; Regulador de Conductancia de Transmembrana de Fibrosis Quística/genética; Aminofenoles/efectos adversos; Disnea/tratamiento farmacológico; Mutación

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrosis Quística Tipo de estudio: Systematic_reviews Límite: Adult / Child / Humans Idioma: En Revista: Cochrane Database Syst Rev Asunto de la revista: PESQUISA EM SERVICOS DE SAUDE Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google